Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Teduglutide (Gattex) vs Vasopressin (Vasostrict)
An educational, source-based comparison of Teduglutide (Gattex) and Vasopressin (Vasostrict) — how each peptide works, what it's researched for, and what to know before going deeper.
GLP-2 analog for short bowel syndrome dependent on parenteral support.
Recombinant analog of glucagon-like peptide-2 with alanine→glycine substitution at position 2, resisting DPP-IV degradation; promotes intestinal mucosal growth, villus height, and absorptive capacity.
- Short bowel syndrome with intestinal failure
- Reduction of parenteral nutrition dependence
- • FDA-approved.
- • Colorectal polyp surveillance required.
- • Risk of intestinal obstruction and biliary/pancreatic disease.
Endogenous nonapeptide that activates V1 vascular receptors to cause vasoconstriction and V2 renal receptors for water reabsorption. Used to raise blood pressure in catecholamine-resistant shock.
- Septic shock
- Cardiac arrest (historical)
- Diabetes insipidus
- • FDA-approved.
- • Ischemic complications possible at high doses.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Teduglutide (Gattex) | STEPS trial | Gastroenterology | 2012 | Reduced parenteral support volume in SBS patients vs placebo. |
| Vasopressin (Vasostrict) | VASST trial | NEJM | 2008 | Vasopressin added to norepinephrine did not reduce mortality overall but benefited less severe septic shock. |
Side-effect & safety grid
- FDA-approved.
- Colorectal polyp surveillance required.
- Risk of intestinal obstruction and biliary/pancreatic disease.
- FDA-approved.
- Ischemic complications possible at high doses.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Teduglutide (Gattex) vs Vasopressin (Vasostrict) — Key differences
- Class: Teduglutide (Gattex) is classified as GLP-2 Analog · Gastrointestinal, while Vasopressin (Vasostrict) is Vasopressor · Hormonal.
- Primary research focus: Teduglutide (Gattex) — short bowel syndrome with intestinal failure; Vasopressin (Vasostrict) — septic shock.
- Tag: FDA-Approved · GI vs FDA-Approved · Critical Care.